Your browser doesn't support javascript.
loading
Kinetic and Angiogenic Activity of Circulating Endothelial Colony Forming Cells in Patients with Infantile Haemangioma Receiving Propranolol.
Campanelli, Rita; Codazzi, Alessia Claudia; Poletto, Valentina; Abbà, Carlotta; Catarsi, Paolo; Fois, Gabriela; Avanzini, Maria Antonietta; Brazzelli, Valeria; Tzialla, Chryssoula; De Silvestri, Annalisa; Tinelli, Carmine; Licari, Amelia; Berra-Romani, Roberto; Zuccolo, Estella; Moccia, Francesco; Mannarino, Savina; Rosti, Vittorio; Massa, Margherita.
Afiliação
  • Campanelli R; Center for the Study of Myelofibrosis, Laboratory of Biochemistry, Biotechnology and Advanced Diagnosis, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
  • Codazzi AC; Cardiology Clinic of Pediatrics, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
  • Poletto V; Center for the Study of Myelofibrosis, Laboratory of Biochemistry, Biotechnology and Advanced Diagnosis, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
  • Abbà C; Center for the Study of Myelofibrosis, Laboratory of Biochemistry, Biotechnology and Advanced Diagnosis, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
  • Catarsi P; Center for the Study of Myelofibrosis, Laboratory of Biochemistry, Biotechnology and Advanced Diagnosis, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
  • Fois G; Center for the Study of Myelofibrosis, Laboratory of Biochemistry, Biotechnology and Advanced Diagnosis, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
  • Avanzini MA; Immunology and Transplantation Laboratory/Cell Factory/Pediatric Haematology/Oncology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
  • Brazzelli V; Department of Clinical-Surgical, Diagnostic and Pediatric Science, Institute of Dermatology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
  • Tzialla C; Neonatal Intensive Care Unit, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
  • De Silvestri A; Epidemiology Service, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
  • Tinelli C; Epidemiology Service, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
  • Licari A; Department of Pediatrics, IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy.
  • Berra-Romani R; Department of Biomedicine, School of Medicine, Benemérita Universidad Autónoma de Puebla, Puebla, México.
  • Zuccolo E; Laboratory of General Physiology, Department of Biology and Biotechnology "Lazzaro Spallanzani," University of Pavia, Pavia, Italy.
  • Moccia F; Laboratory of General Physiology, Department of Biology and Biotechnology "Lazzaro Spallanzani," University of Pavia, Pavia, Italy.
  • Mannarino S; Cardiology Clinic of Pediatrics, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
  • Rosti V; Center for the Study of Myelofibrosis, Laboratory of Biochemistry, Biotechnology and Advanced Diagnosis, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
  • Massa M; Laboratory of Biochemistry, Biotechnology and Advanced Diagnosis, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
Thromb Haemost ; 119(2): 274-284, 2019 Feb.
Article em En | MEDLINE | ID: mdl-30609443
Endothelial progenitor cells (EPCs) have been suggested to contribute to the neovascularization of infantile haemangioma (IH). There is strong evidence of the efficacy of propranolol in the treatment of IH, possibly by inhibiting both vasculogenesis and angiogenesis in the tumour. We evaluate the frequency of circulating endothelial colony forming cells (ECFCs), as the best EPC surrogate, in patients with IH at diagnosis and while receiving propranolol by an ex vivo 12-month longitudinal study. Biological aspects of the ECFCs, such as their in vitro angiogenic potential, membrane CXCR4 expression and Ca2+ signalling, were investigated. Circulating ECFCs were isolated by in vitro culture and expanded for 2 to 3 passages in 23 patients with IH (median age: 5.5 months, range: 5.5 weeks-11 months) before and 3, 6, 9 and 12 months after receiving propranolol. Twenty-four healthy subjects comparable for age were also assessed (CTRLs). Untreated patients with IH had a circulating ECFC frequency lower (p = 0.001) than CTRLs; nevertheless, in in vitro starving conditions, ECFCs showed enhanced capacity to form tube-like structures than those of CTRLs. Patients with IH following the therapy with propranolol had a significantly increased (p = 0.022) circulating ECFC frequency, that showed a diminished tube-like formation capacity in vitro, and an altered constitutive store-operated Ca2+ entry. ECFCs play a role in IH pathogenesis; the response to propranolol therapy is associated with their increased frequency in the peripheral blood and a reduction of their vasculogenic activity.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Propranolol / Células Endoteliais / Hemangioma / Neovascularização Patológica Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Propranolol / Células Endoteliais / Hemangioma / Neovascularização Patológica Idioma: En Ano de publicação: 2019 Tipo de documento: Article